AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
13.95
14.37
년간 변동
4.71
18.61
일일 변동
+0.91%
월간 변동
-8.19%
6달 변화
-2.18%
년간 변동율
+188.73%
이전 종가
14.2 2
Open
14.0 1
저가
13.9 5
High
14.3 7
양
666
전체 차트 열기 Full chart

Financials

개요 성명 통계 배당금
4분기 연간
  • Market Capitalization 1.6 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-7.9
주가매출액비율
—

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

뉴스